Cited by 659CAR-T cell therapy researchImmunotherapy and Immune ResponsesCRISPR and Genetic Engineering

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Open access

Ruella, Marco, Xu, Jun, Barrett, David M., Fraietta, Joseph A., Reich, Tyler J., Ambrose, David E., Klichinsky, Michael, Shestova, Olga, Patel, Prachi R., Kulikovskaya, Irina, Nazimuddin, Farzana, Bhoj, Vijay G., Orlando, Elena J., Fry, Terry J., Bitter, Hans, Maude, Shannon L., Levine, Bruce L., Nobles, Christopher L., Bushman, Frederic D., Young, Regina M., Scholler, John, Gill, Saar I., June, Carl H., Grupp, Stephan A., Lacey, Simon F., Melenhorst, J. Joseph·2018·Nature Medicine

DOI 10.1038/s41591-018-0201-9PMC PMC6511988

Open this paper in CoChat — free account

Abstract

We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0201-9

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citation
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citation
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation

Show all 36 references

Research works printed but not linked: 1

Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Clin. Cancer Res. 8, 995–1002 (2002).

Sorted by citations

Items 301–400 of 659

Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Locatelli, F., Bufalo, F. D., & Quintarelli, C. (2024) · Haematologica · doi:10.3324/haematol.2023.284604 · Cited by 19
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma
Rogers, A. M., & Brammer, J. E. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00590-5 · Cited by 18
Improving CAR T-cells: The next generation
Marple, A., Bonifant, C. L., & Shah, N. N. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.002 · Cited by 18
The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead
Reddy, S. R., Llukmani, A., Hashim, A., Haddad, D. R., Patel, D. S., Ahmad, F., Sneineh, M. A., & Gordon, D. K. (2021) · Cureus · doi:10.7759/cureus.13552 · Cited by 17
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy
Im, N. G., Guillaumet-Adkins, A., Wal, M., Rogers, A. J., Frede, J., Havig, C. C., Yang, J., Anand, P., Stegmann, S. K., Waldschmidt, J. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0626 · Cited by 17
Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering
Obeng, E. M., Fulcher, A. J., & Wagstaff, K. M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108108 · Cited by 21
Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
Xu, H., Li, N., Wang, G., & Cao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110028 · Cited by 17
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies
Salas‐Benito, D., Berger, T. R., & Maus, M. V. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012235 · Cited by 17
RNA-loaded nanoparticles for the treatment of hematological cancers
Garbayo, E., Moukhtari, S. H. E., Rodríguez‐Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodríguez-Márquez, P., Prósper, F., Couvreur, P., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 19
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 20
Self-citation
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
Valand, H. A., Huda, F., & Tu, R. K. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6042 · Cited by 17
CART manufacturing process and reasons for academy-pharma collaboration
Egri, N., de Landazuri, I. O., Bartolomé, C. S., Ortega, J. R., Español‐Rego, M., & Juan, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.10.014 · Cited by 18
Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
Laurent, E., Sieber, A., Salzer, B., Wachernig, A., Seigner, J., Lehner, M., Geyeregger, R., Kratzer, B., Jaeger, U., Kunert, R., et al. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00010 · Cited by 17
Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence
Sun, W., Jiang, Z., Jiang, W. G., & Yang, R. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100638 · Cited by 17
Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together
Bernard, G., & Evgin, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664403 · Cited by 14
Innovative gene engineering strategies to address tumor antigen escape in cell therapy
Chen, Y., Niu, S., Li, Y.-R., & Yang, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07259-8 · Cited by 19
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
Heyman, B. M., Tzachanis, D., & Kipps, T. J. (2022) · Cancers · doi:10.3390/cancers14071715 · Cited by 17
Application and Design of Switches Used in CAR
Głowacki, P., & Rieske, P. (2022) · Cells · doi:10.3390/cells11121910 · Cited by 18
Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells
Kruglova, N. A., & Shepelev, M. V. (2024) · Biomedicines · doi:10.3390/biomedicines12010119 · Cited by 18
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models
Jamali, A., Ho, N., Braun, A., Adabi, E., Thalheimer, F. B., & Buchholz, C. J. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00055-9 · Cited by 17
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review
Tang, C., & Zhang, Y. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155518 · Cited by 19
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells
Weiss, R., Gerdes, W., Berthold, R., Sack, U., Koehl, U., Hauschildt, S., & Grahnert, A. (2021) · Cells · doi:10.3390/cells10112824 · Cited by 15
“Off-the-Shelf” Allogeneic CAR Cell Therapy—Neglected HvG Effect
An, Y., Jin, X. K., Zhang, H., Zhang, M., Mahara, S., Lu, W., & Zhao, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01061-8 · Cited by 15
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 17
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial
Zhao, L., Li, C., Zuo, S., Han, Y., Deng, B., Ling, Z., Zhang, Y., Peng, S., Xu, J., Duan, J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.006 · Cited by 15
Self-citation
Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus
Rive, C. M., Yung, E., Dreolini, L., Brown, S. D., May, C. G., Woodsworth, D. J., & Holt, R. A. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.006 · Cited by 14
Therapeutic Advances in Immunotherapies for Hematological Malignancies
Nogami, A., & Sasaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911526 · Cited by 14
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
Angelos, M. G., Patel, R. P., Ruella, M., & Barta, S. K. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.013 · Cited by 16
Self-citation
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity
Ma, R., Woods, M. L., Burkhardt, P. M., Crooks, N., van Leeuwen, D. G., Shmidt, D. I., Couturier, J. P., Chaumette, A., Popat, D., Hill, L. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101628 · Cited by 17
Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy
Floss, D. M., & Scheller, J. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.05.007 · Cited by 14
Advances and Challenges of CAR T Cells in Clinical Trials
Holzinger, A., & Abken, H. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_3 · Cited by 14
Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
Borrok, M. J., Li, Y., Harvilla, P. B., Maruthachalam, B. V., Tamot, N., Prokopowitz, C., Chen, J., Venkataramani, S., Grewal, I. S., Ganesan, R., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0150 · Cited by 14
Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies
Dhakal, B., Chhabra, S., Savani, B. N., & Hamadani, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17904 · Cited by 14
In vivo nano-engineering T cells for CAR-T therapy
Shi, T., Li, Y., Deng, C., Ren, Q., Xu, C., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114379 · Cited by 17
Overcoming key challenges in cancer immunotherapy with engineered T cells
Arcangeli, S., Mestermann, K., Weber, J., Bonini, C., Casucci, M., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000664 · Cited by 13
Novel immunotherapies in multiple myeloma
Ohmine, K., & Uchibori, R. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03365-1 · Cited by 13
CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes
Kapitza, L., Ho, N., Kerzel, T., Frank, A. M., Thalheimer, F. B., Jamali, A., Schaser, T., Buchholz, C. J., & Hartmann, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183698 · Cited by 13
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer
Anupindi, K., Malachowski, J., Hodson, I., Zhu, D., June, C. H., & Levine, B. L. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.010 · Cited by 13
Self-citation
TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product
Straetemans, T., Janssen, A., Jansen, K., Doorn, R., Aarts, T., van Muyden, A. D. D., Simonis, M., Bergboer, J., de Witte, M., Sebestyen, Z., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.030 · Cited by 13
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14
A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies
Newman, H. M., & Teachey, D. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158600 · Cited by 12
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
Savelli, C. B., Clerico, M., Botto, B., Secreto, C., Cavallo, F., Dellacasa, C. M., Busca, A., Bruno, B., Freilone, R., Cerrano, M., et al. (2023) · Cancers · doi:10.3390/cancers16010046 · Cited by 13
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadiñanos-Garai, A., Vispute, K., Bosshard‐Carter, L., Mitsikakou, M., Charalambous, E., Mehra, V., et al. (2025) · Blood · doi:10.1182/blood.2025028790 · Cited by 12
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
Hoseini, S. S., Espinosa-Cotton, M. M., Guo, H.-F., & Cheung, N. V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001626 · Cited by 12
Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer
Cordes, N., Winter, N., Kolbe, C., Kotter, B., Mittelstaet, J., Assenmacher, M., Cathomen, T., Kaiser, A., & Schaser, T. (2022) · Viruses · doi:10.3390/v14102157 · Cited by 12
CAR Chase: Where Do Engineered Cells Go in Humans?
Krebs, S. S., Dacek, M. M., Carter, L. M., Scheinberg, D. A., & Larson, S. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.577773 · Cited by 13
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 14
Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma
Quach, D. H., Ganesh, H. R., Briones, Y. D., Nouraee, N., Ma, A., Hadidi, Y. F., Sharma, S., & Rooney, C. M. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200814 · Cited by 12
AAVS1 site‐specific integration of the CAR gene into human primary T cells using a linear closed‐ended AAV‐based DNA vector
Chen, W., Tan, L., Zhou, Q., Li, W., Li, T., Zhang, C., & Wu, J. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3157 · Cited by 11
Dielectrophoretic high-purity isolation of primary T-cells in samples contaminated with leukemia cells, for biomanufacturing of therapeutic CAR T-cells
Ringwelski, B., Jayasooriya, V., & Nawarathna, D. (2020) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/abc2f3 · Cited by 11
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia
Viardot, A., & Sala, E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1928074 · Cited by 11
A T-cell independent universal cellular therapy strategy through antigen depletion
Li, D., Wang, W., Xie, S., Ge, M., Wang, R., Xu, Q., Sun, Y., Zhu, J., & Liu, H. (2022) · Theranostics · doi:10.7150/thno.66832 · Cited by 11
An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
Wu, X., & Schmidt‐Wolf, I. G. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.913123 · Cited by 11
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
Xie, D., Jin, X. K., Sun, R., Zhang, M., Wang, J., Xiong, X., Zhang, X., & Zhao, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221118413 · Cited by 11
Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors
Braun, A., Frank, A. M., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.002 · Cited by 11
How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19 ‐directed chimeric antigen receptor T cells
Nagler, A., Perriello, V. M., Falini, L., & Falini, B. (2023) · British Journal of Haematology · doi:10.1111/bjh.18724 · Cited by 13
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Lulla, P., Mamonkin, M., & Brenner, M. K. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000376 · Cited by 16
Overcoming Challenges in Process Development of Cellular Therapies
Highfill, S. L., & Stroncek, D. F. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00529-5 · Cited by 12
Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study
Huang, C., Wu, L., Liu, R., Li, W., Zheng, L., Li, J., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4363 · Cited by 10
Interfacing Biomaterials with Synthetic T Cell Immunity
Su, F., Mac, Q. D., Sivakumar, A., & Kwong, G. A. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100157 · Cited by 10
Why Immunotherapy Fails in Multiple Myeloma
Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Moreno, D. F., de Larrea, C. F., & Bladé, J. (2020) · Hemato · doi:10.3390/hemato2010001 · Cited by 11
Adventures in the Classroom Creating Role-Playing Games Based on Traditional Stories for the High School Curriculum
Zalka, C. V. (2012) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 11
CAR-based cell therapy for autoimmune diseases
Li, X., He, C. S., Wang, X., Xu, G., Xie, Y., & Ying, X.-Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613622 · Cited by 10
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 14
Characterization of leukemic resistance to CD19-targeted CAR T-cell therapy through deep genomic sequencing
Chen, G. M., Chen, C.-H., Perazzelli, J., Grupp, S., Barrett, D., & Tan, K. (2022) · Cancer immunology research · doi:10.1158/2326-6066.cir-22-0095 · Cited by 8
Self-citation
Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies
Gao, X., Liu, J., Sun, R., Zhang, J., Cao, X., Zhang, Y., & Zhao, M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05488-9 · Cited by 10
The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases
Liu, Z., Xiao, Y., Lyu, J., Jing, D., Liu, L., Fu, Y., Niu, W., Jin, L., & Zhang, C. (2023) · Protein & Cell · doi:10.1093/procel/pwad061 · Cited by 10
CAR T-cells for T-cell acute lymphoblastic leukemia
Dourthe, M.-É., & Baruchel, A. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100150 · Cited by 9
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 11
Application and prospects of genetic engineering in CAR-NK cell therapy
Hu, C., Lai, W., Tian, B., Xu, X., Xie, S., Zhong, W., Kang, H., Chen, X., Li, H.-L., Xu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600411 · Cited by 12
Self-citation
[Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
Zuo, Y., Jia, Y., Wu, J., Wang, J., Lu, A., Dong, L., Chang, L., & Zhang, L. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.04.002 · Cited by 10
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes
Jain, M. D., & Spiegel, J. Y. (2021) · eJHaem · doi:10.1002/jha2.357 · Cited by 10
Rapid generation of CD19 CAR-T cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia
Ye, X., Wu, Y., Zhang, H., Shi, L., Zhou, Y., Guo, S., Dong, J., & Cai, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216278 · Cited by 10
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
Vitale, C., Griggio, V., Perutelli, F., & Coscia, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000988 · Cited by 10
CAR‐T cells beyond CD19, UnCAR‐Ted territory
Leick, M. B., & Maus, M. V. (2019) · American Journal of Hematology · doi:10.1002/ajh.25398 · Cited by 10
Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy
Shi, P. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000611 · Cited by 10
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Cai, Q., Zhang, M., & Li, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920962963 · Cited by 10
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
Quintarelli, C., Guercio, M., Manni, S., Boffa, I., Sinibaldi, M., Cecca, S. D., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001514 · Cited by 10
Self-citation
Chimeric Antigen Receptor T-cell Therapy
Talleur, A. C., Myers, R. M., Annesley, C., & Shalabi, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.005 · Cited by 11
Research advances of nanoparticles for CAR-T therapy in solid tumors
Chen, B., Gong, L., Feng, J. Q., Jin, M., Chen, L., Gao, Z., & Huang, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109432 · Cited by 10
Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy
Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. (2024) · Advanced Materials · doi:10.1002/adma.202407525 · Cited by 11
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection
Velázquez, S. N., Moukheiber, C., Inogés, S., Guillén, M. R., de Cerio, A. L.-D., Sanges, C., Tanaka, T., Arnould, S., Briones, J., Dolstra, H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.017 · Cited by 9
From Ex Vivo to In Vivo : Advances in Lentiviral Vector Engineering for CAR-T Therapy
Baek, Y., Seo, Y. R., Kim, S., Jung, S., Kim, C. H., & Lee, Y.-H. (2026) · Immune Network · doi:10.4110/in.2026.26.e13 · Cited by 9
Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)
Fu, Z., Zhou, J., Chen, R., Jin, Y.-H., Ni, T., Qian, L.-B., & Xiao, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11897 · Cited by 10
Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy
Diamanti, P., Cox, C. V., Ede, B. C., Uger, R. A., Moppett, J. P., & Blair, A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003534 · Cited by 9
When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies
Dai, X., Li, J., Chen, Y., & Ostrikov, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837995 · Cited by 9
TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
Shaw, L. C., Poussin, M., Rodríguez-García, A., Eggold, J. T., Minutolo, N. G., Wang, J., Rook, A. H., Schuster, S. J., & Powell, D. J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008798 · Cited by 9
T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources
Bonte, S., Munter, S. D., Goetgeluk, G., Ingels, J., Pille, M., Billiet, L., Taghon, T., Leclercq, G., Vandekerckhove, B., & Kerre, T. C. C. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1727078 · Cited by 9
Sortase-A mediated chemoenzymatic lipidation of single-domain antibodies for cell membrane engineering
Wöll, S., Bachran, C., Schiller, S., Swee, L. K., & Scherließ, R. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.05.019 · Cited by 9
Current status and hurdles for CAR-T cell immune therapy
Zhao, R., Cui, Y., Li, S., Qin, L., & Li, P. (2019) · Blood Science · doi:10.1097/bs9.0000000000000025 · Cited by 11
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
Al-Juhaishi, T. M. S., & Ahmed, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00615-7 · Cited by 9
Engineered T Cell Therapies from a Drug Development Viewpoint
Chen, F., Fraietta, J. A., June, C. H., Xu, Z., Melenhorst, J. J., & Lacey, S. F. (2018) · Engineering · doi:10.1016/j.eng.2018.11.010 · Cited by 9
Self-citation
Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment
Hung, L. V. M., Ngo, H. T., & Pham, P. V. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_522 · Cited by 9
CAR T cells for other pediatric non–B-cell hematologic malignancies
Lamble, A. J., & Gardner, R. A. (2020) · Hematology · doi:10.1182/hematology.2020000134 · Cited by 9
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Zhao, H., Wang, Y., Yin, E. T. S., Zhao, K., Hu, Y., & Huang, H. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0808-3 · Cited by 9
Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen
Adotévi, O., & Galaine, J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1739 · Cited by 9
Functional diversification and dynamics of CAR-T cells in patients with B-ALL
Li, Z., Zhao, L., Zhang, Y., Zhu, L., Mu, W., Ge, T., Jin, J., Tan, J., Cheng, J., Wang, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113263 · Cited by 10
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Teo, P. Y., Jung, Y., Quach, D. H., Koh, J., Ong, R., Goh, A. X., Tan, A. S. M., Ng, C. H., Seh, C. C., Tan, K. W., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1001 · Cited by 8
Amphiphilic Polyaspartamide Derivatives with Cholesterol Introduction Enhanced Ex Vivo mRNA Transfection Efficiency to Natural Killer Cells
Koam, D., Park, H. Y., Kim, D. S., Kwon, H. J., Lee, Y., Kim, K., Naito, M., & Kim, H. J. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01411 · Cited by 8

Authors: Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., & Melenhorst, J. J.
Affiliations: Abramson Cancer Center (US)
Children's Hospital of Philadelphia (US)
University of Pennsylvania (US)
Children's Hospital Colorado (US)
Corresponding author: June, Carl H.
Melenhorst, J. Joseph
ORCID: Ruella, Marco
Xu, Jun
Barrett, David M.
Fraietta, Joseph A.
Reich, Tyler J.
Klichinsky, Michael
Patel, Prachi R.
Kulikovskaya, Irina
Bhoj, Vijay G.
Orlando, Elena J.
Fry, Terry J.
Bitter, Hans
Maude, Shannon L.
Levine, Bruce L.
Nobles, Christopher L.
Bushman, Frederic D.
Young, Regina M.
Scholler, John
Gill, Saar I.
June, Carl H.
Grupp, Stephan A.
Lacey, Simon F.
Melenhorst, J. Joseph
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2018-10
Volume: 24
Issue: 10
Pages: 1499-1503
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-018-0201-9
PMC: PMC6511988
OpenAlex: W2893691711
Cited by: 659
References: 36
Citations by year: 2026: 61 · 2025: 73 · 2024: 83 · 2023: 84 · 2022: 83 · 2021: 91 · 2020: 91 · 2019: 78 · 2018: 14
FWCI: 25.75
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K99CA212302, R00CA212302, T32CA009140, R01CA120409, P01CA214278)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords: CAR T-cell therapy, CD19, tisagenlecleucel, B-cell acute lymphoblastic leukemia, CAR T cell manufacturing, relapse
MeSH terms: Receptors, Chimeric Antigen, Adult, Epitopes, B-Lymphocytes, Humans, Leukemia, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Antigens, CD19, Drug Resistance, Neoplasm, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks